News Home

Will Halozyme Therapeutics, Inc. (HALO) Stay at the Top of the Healthcare Sector?

Monday, September 20, 2021 03:17 PM | InvestorsObserver Analysts
Will Halozyme Therapeutics, Inc. (HALO) Stay at the Top of the Healthcare Sector?

The 74 rating InvestorsObserver gives to Halozyme Therapeutics, Inc. (HALO) stock puts it near the middle of the Healthcare sector. In addition to scoring higher than 64 percent of stocks in the Healthcare sector, HALO’s 74 overall rating means the stock scores better than 74 of all stocks.

Overall Score - 74
HALO has an Overall Score of 74. Find out what this means to you and get the rest of the rankings on HALO!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 74 means the stock is more attractive than 74 percent of stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Halozyme Therapeutics, Inc. Stock Today?

Halozyme Therapeutics, Inc. (HALO) stock is trading at $40.93 as of 3:16 PM on Monday, Sep 20, a loss of -$1.11, or -2.64% from the previous closing price of $42.04. The stock has traded between $40.92 and $41.92 so far today. Volume today is less active than usual. So far 435,296 shares have traded compared to average volume of 804,717 shares. Click Here to get the full Stock Report for Halozyme Therapeutics, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App